Last reviewed · How we verify

NCT05210777

Norms and Validation for IntelliSpace Cognition Spanish Version

Completed Last updated 18 July 2022
What this trial tests

trial testing observation in Cognitive Functioning of Healthy Individuals in 99 participants. Completed in 19 May 2022.

Timeline
31 January 2022
Primary endpoint
15 April 2022
19 May 2022

Quick facts

Lead sponsorPhilips Electronics Nederland B.V. acting through Philips CTO organization
StatusCompleted
Study typeOBSERVATIONAL
Enrollment99
Start date31 January 2022
Primary completion15 April 2022
Estimated completion19 May 2022
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Philips Electronics Nederland B.V. acting through Philips CTO organization

Who can join

18 and older, any sex, with Cognitive Functioning of Healthy Individuals or Hispanic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to validate and provide applicable norms for the United States (US) Spanish versions of the IntelliSpace Cognition (ISC) neuropsychological tests.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of observation

Trials testing the same drug.

Other Philips Electronics Nederland B.V. acting through Philips CTO organization trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210777.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing